Therapeutic potential of Pak1 inhibition for pain associated with cutaneous burn injury

Area of Science:

• Neuroscience
• Pain Research
• Molecular Biology

Background:

• Burn injuries cause debilitating chronic pain, a significantly under-studied condition.
• The Rac1-signaling pathway contributes to neuropathic pain, but Rac1 itself has limited therapeutic potential.
• Pak1, a downstream effector of Rac1, is implicated in neurological diseases and cognitive dysfunction.

Purpose of the Study:

• To investigate the role of Pak1 in burn-induced neuropathic pain.
• To test the hypothesis that inhibiting Pak1 improves pain outcomes after burn injury.
• To evaluate romidepsin, an FDA-approved inhibitor, for treating burn-related neuropathic pain.

Main Methods:

• A longitudinal study in a mouse model of second-degree burn injury.
• Assessment of tactile allodynia, heat hyperalgesia, and dendritic spine morphology.
• Measurement of c-fos expression in dorsal horn neurons as a marker of nociceptive activity.
• Treatment with romidepsin to inhibit Pak1 and observation of pain behaviors and cellular changes post-treatment and after drug discontinuation.

Main Results:

• Burn injury induced significant tactile allodynia, heat hyperalgesia, and dendritic spine dysgenesis in the dorsal horn.
• Increased c-fos expression indicated elevated central nociceptive activity.
• Romidepsin treatment reduced dendritic spine dysgenesis, decreased c-fos expression, and restored normal pain thresholds.
• Discontinuation of romidepsin led to a relapse of pain behaviors and cellular changes.

Conclusions:

• Pak1 signaling is a key mediator of neuropathic pain following burn injury.
• Inhibiting Pak1 with romidepsin demonstrates therapeutic potential for managing burn-induced pain.
• Pak1 represents a promising molecular target for developing novel treatments for chronic pain after burns.